Miles Wang, an OpenAI researcher, is leaving to start an AI drug discovery company aiming for a $2 billion valuation with a $200 million funding round. This move reflects growing investor interest in AI applications within life sciences, following recent significant funding in the sector.
Miles Wang, a researcher from OpenAI, is set to launch a new startup focusing on AI models for drug discovery. The company aims to leverage AI to discover new applications for existing drugs, potentially unlocking faster paths to revenue by utilizing already-approved medications.
The startup is reportedly in discussions to raise approximately $200 million at a valuation of $2 billion. Lightspeed Venture Partners is interested in leading this funding round, although the talks are ongoing and not finalized.
The conversations around Wang's startup indicate a robust interest from investors in employing AI to drive innovations in life sciences. Recent high-profile funding rounds, such as Chai Discovery's $400 million at a $3.8 billion valuation and Isomorphic Labs' $2.1 billion Series B, highlight the trend of increasing investment in AI-driven drug development.
Miles Wang joined OpenAI in 2024 after leaving Harvard during his computer science studies. At OpenAI, he contributed to research on how AI can enhance scientific discovery and automation, informing his move to the new startup. Wang's decision reflects a growing trend of investing in young entrepreneurs without complete academic credentials.
✨ This summary was generated by AI from the outlets' reporting listed below. It is not independently verified and may contain errors — check the original sources. How BrevFeed works →
Miles Wang, an OpenAI researcher, is leaving to start an AI drug discovery company aiming for a $2 billion valuation with a $200 million funding round. This move reflects growing investor interest in AI applications within life sciences, following recent significant funding in the sector.